Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Recent advances in understanding the genetics of pancreatic ductal adenocarcinoma (PDAC) have led to the potential for a personalized approach. Several studies have described the feasibility of generating genetic profiles of PDAC with next-generation sequencing (NGS) of samples obtained through endoscopic ultrasound-guided tissue acquisition (EUS-TA). The aim of this study was to find the best EUS-TA approach for successful NGS of PDAC. Methods: We attempted to perform NGS with tissues from 190 patients with histologically proven PDAC by endoscopic ultrasound-guided fine-needle aspiration and endoscopic ultrasound-guided fine-needle biopsy at Samsung Medical Center between November 2011 and February 2015. The medical records of these patients were retrospectively reviewed for parameters including tumor factors (size, location, and T stage), EUS-TA factors (needle gauge [G], needle type, and number of needle passes) and histologic factors (cellularity and blood contamination). The sample used for NGS was part of the EUS-TA specimen that underwent cytological and histological analysis. Results: NGS could be successfully performed in 109 patients (57.4%). In the univariate analysis, a large needle G (p=0.003) and tumor located in the body/tail (p=0.005) were associated with successful NGS. The multivariate logistic regression analysis revealed that the needle G was an independent factor of successful NGS (odds ratio, 2.19; 95% confidence interval, 1.08 to 4.47; p=0.031). Conclusions: The needle G is an independent factor associated with successful NGS. This finding may suggest that the quantity of cells obtained from EUS-TA specimens is important for successful NGS.
Abstract
Background/Aims: Recent advances in understanding the genetics of pancreatic ductal adenocarcinoma (PDAC) have led to the potential for a personalized approach. Several studies have described the feasibility of generating genetic profiles of PDAC with next-generation sequencing (NGS) of samples obtained through endoscopic ultrasound-guided tissue acquisition (EUS-TA). The aim of this study was to find the best EUS-TA approach for successful NGS of PDAC. Methods: We attempted to perform NGS with tissues from 190 patients with histologically proven PDAC by endoscopic ultrasound-guided fine-needle aspiration and endoscopic ultrasound-guided fine-needle biopsy at Samsung Medical Center between November 2011 and February 2015. The medical records of these patients were retrospectively reviewed for parameters including tumor factors (size, location, and T stage), EUS-TA factors (needle gauge [G], needle type, and number of needle passes) and histologic factors (cellularity and blood contamination). The sample used for NGS was part of the EUS-TA specimen that underwent cytological and histological analysis. Results: NGS could be successfully performed in 109 patients (57.4%). In the univariate analysis, a large needle G (p=0.003) and tumor located in the body/tail (p=0.005) were associated with successful NGS. The multivariate logistic regression analysis revealed that the needle G was an independent factor of successful NGS (odds ratio, 2.19; 95% confidence interval, 1.08 to 4.47; p=0.031). Conclusions: The needle G is an independent factor associated with successful NGS. This finding may suggest that the quantity of cells obtained from EUS-TA specimens is important for successful NGS.
참고문헌 (29)
- Jemal A, "Cancer statistics, 2010", CA Cancer J Clin, 60, pp.277~300 (2010)
- Mayo SC, "Management of patients with pancreatic adenocarcinoma : national trends in patient selection, operative management, and use of adjuvant therapy", J Am Coll Surg, 214, pp.33~45 (2012)
- Mayo SC, "Adjuvant therapy and survival after resection of pancreatic adenocarcinoma : a population-based analysis", Cancer, 116, pp.2932~2940 (2010)
- 김용태, "췌장암의 항암화학요법", 대한소화기학회지, 51(2), pp.111~118 (2008), 대한소화기학회
- Peyvandi F, "Caplacizumab for acquired thrombotic thrombocytopenic purpura", N Engl J Med, 374, pp.511~522 (2016)
- Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
- Sadot E, "FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma", Ann Surg Oncol, 22, pp.3512~3521 (2015)
- Guan YF, "Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer", Chin J Cancer, 31, pp.463~470 (2012)
- Mardis ER, "Applying next-generation sequencing to pancreatic cancer treatment", Nat Rev Gastroenterol Hepatol, 9, pp.477~486 (2012)
- Crane CH, "Keys to personalized care in pancreatic oncology", J Clin Oncol, 30, pp.4049~4050 (2012)
- Humphris J, "Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing", Gastroenterology, 148, pp.496~498 (2015)
- Waddell N, "Whole genomes redefine the mutational landscape of pancreatic cancer", Nature, 518, pp.495~501 (2015)
- Jones S, "Core signaling pathways in human pancreatic cancers revealed by global genomic analyses", Science, 321, pp.1801~1806 (2008)
- Villarroel MC, "Personalizing cancer treatment in the age of global genomic analyses : PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer", Mol Cancer Ther, 10, pp.3~8 (2011)
- Iacobuzio-Donahue CA, "DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer", J Clin Oncol, 27, pp.1806~1813 (2009)
- Biankin AV, "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes", Nature, 491, pp.399~405 (2012)
- Lee JK, "A prospective, randomized trial comparing 25-gauge and 22-gauge needles for endoscopic ultrasound-guided fine needle aspiration of pancreatic masses", Scand J Gastroenterol, 48, pp.752~757 (2013)
- Valero V 3rd, "Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing : implications for surgical management", Ann Surg, 263, pp.153~161 (2016)
- Lee JK, "A prospective, comparative trial to optimize sampling techniques in EUS-guided FNA of solid pancreatic masses", Gastrointest Endosc, 77, pp.745~751 (2013)
- Gleeson FC, "Lung cancer adrenal gland metastasis : optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing", Cancer Cytopathol, 122, pp.822~832 (2014)
- Karnes HE, "Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung", Cancer Cytopathol, 122, pp.104~113 (2014)
- Kubota Y, "CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing", J Gastroenterol, 50, pp.203~210 (2015)
- Young G, "Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms", Cancer Cytopathol, 121, pp.688~694 (2013)
- de Biase D, "Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions", PLoS One, 9, pp.e87651~ (2014)
- Lee JY, "Patient-derived cell models as preclinical tools for genome-directed targeted therapy", Oncotarget, 6, pp.25619~25630 (2015)
- Wang J, "Endoscopic ultrasound guided fine needle aspiration versus endoscopic ultrasound guided fine needle biopsy in sampling pancreatic masses: a meta-analysis", Medicine(Baltimore), 96, pp.e7452~ (2017)
- Gleeson FC, "Characterization of endoscopic ultrasound fine-needle aspiration cytology by targeted next-generation sequencing and theranostic potential", Clin Gastroenterol Hepatol, 13, pp.37~41 (2015)